News by community

09.02.2017 Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT

  • 421 patients randomized at 38 European trial centers
  • Top-line results expected in Q3, 2017

 

EPALINGES, Switzerland, February 8, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.

More information

back